| Nov 15 |
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
|
| Nov 4 |
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 4 |
Precision BioSciences: Q3 Earnings Snapshot
|
| Nov 4 |
Precision BioSciences GAAP EPS of -$2.25, revenue of $0.6M
|
| Nov 4 |
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 1 |
Precision BioSciences Q3 2024 Earnings Preview
|
| Nov 1 |
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?
|
| Oct 29 |
Precision BioSciences to Report Third Quarter Results on November 4, 2024
|
| Oct 28 |
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
|
| Oct 24 |
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
|
